Treatment of plaque psoriasis with the two-compound product... (2010)

Title Treatment of plaque psoriasis with the two-compound product calcipotriol/betamethasone dipropionate versus both monotherapies: An immunohistochemical study.
Published in Journal of Dermatological Treatment, Vol. 21, p.13-22. ISSN 0954-6634.
Author Velden, H.M.J. van der; Pasch, M.C.; Erp, P.E.J. van; Lingen, R.G. van; Kooijmans-Otero, M.E.; Boer-van Huizen, R.T. de; Kerkhof, P.C.M. van de
Date 2010
Type Article
Abstract The combination of calcipotriol (Cp) and topical corticosteroids increases efficacy and reduces side effects as compared to monotherapies. Previous studies suggest that such combinations may have an added value with respect to reduction of T-cell subsets. A two-compound product consisting of Cp and betamethasone dipropionate (BD) has become available for the treatment of psoriasis and is clinically superior to both monotherapies. No immunohistochemical data are available on the in vivo effects of the two-compound formulation versus monotherapy with respect to the three key processes in psoriasis pathogenesis: epidermal proliferation, epidermal differentiation and inflammation. Therefore, 18 patients were treated with the two-compound product, Cp monotherapy or BD monotherapy for 6 weeks and biopsies were taken before and after 4 and 6 weeks of treatment. These biopsies were stained immunohistochemically and analysed (semi)quantitatively. All treatments decreased the number of Ki-67(+) cells and increased the keratin 15(+) staining. A more pronounced reduction of epidermal and dermal T-cell markers and human beta defensin-2 was seen following combination treatment, compared with both monotherapies. In conclusion, the investigated markers of the skin immune system and epidermal proliferation indicated an added value of the two-compound product over both monotherapies.
OpenURL Search this publication in (your) library
Persistent Identifier urn:nbn:nl:ui:22-2066/87621
Metadata XML
Source Radboud University Nijmegen

Go to page top
Go back to contents
Go back to site navigation